news-pressrelease | Tessa Therapeutics – Cancer Immunotherapy Treatments

What are you looking for?

- home-featured
- news-pressrelease
Tessa Therapeutics Announces Collaboration with A*STAR’s Institute of Molecular and Cell Biology to Form Cell Therapy Laboratory

Tessa Therapeutics today announced a collaboration agreement with the Agency for Science Technology and Research’s…
Continue Reading
- home-featured
- news-pressrelease
Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, “Off-the-Shelf” Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

Tessa Therapeutics today announced early clinical results for an allogeneic CD30-CAR EBVST therapy (TT11X), being…
Continue Reading
- home-featured
- news-pressrelease
Tessa Therapeutics’ Allogeneic, “Off-the-Shelf” CD30 Cell Therapy to be Featured in Podium Presentation at the ASGCT 24th Annual Meeting

Tessa Therapeutics today announced that early clinical data from a Phase 1 dose-escalation study of…
Continue Reading
- home-featured
- news-pressrelease
Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

Tessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial…
Continue Reading
- home-featured
- news-pressrelease
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial

Tessa Therapeutics today announced the successful completion of dosing of the first patient cohort (n=3)…
Continue Reading
- home-featured
- news-pressrelease
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

Tessa Therapeutics today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME)…
Continue Reading
Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer

Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over…
Continue Reading
Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma

Tessa Therapeutics today announced the publication of results in the Journal of Clinical Oncology from…
Continue Reading
Tessa Therapeutics Announces New Executive Leadership

Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive…
Continue Reading
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma

RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical studies conducted by…
Continue Reading